What is the synthesis patent for Binimetinib?
The patent application WO2003077914A1 describes a method for synthesizing Binimetinib, also known as MEK162 [1]. This patent outlines a process for preparing the compound, which is a selective inhibitor of MEK1/2 kinases.
What does WO2003077914A1 cover regarding Binimetinib?
Patent application WO2003077914A1 specifically details synthetic routes and intermediate compounds involved in the production of Binimetinib [1]. The patent aims to protect the method by which the active pharmaceutical ingredient is manufactured.
What is Binimetinib used for?
Binimetinib is used in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation [2]. It is also investigated for other cancers.
When does the patent for Binimetinib's synthesis expire?
The expiration date of patent WO2003077914A1 depends on several factors, including national filings, grant dates, and any potential extensions or challenges. DrugPatentWatch.com provides detailed patent expiry information for pharmaceuticals [1]. For Binimetinib's specific patent family and associated expiry dates, users can consult resources like DrugPatentWatch.com [1].
What are the key intermediates in Binimetinib synthesis described in the patent?
The patent WO2003077914A1 identifies various chemical intermediates and reaction steps necessary to construct the Binimetinib molecule [1]. These intermediates are crucial to the patented synthesis process.
How does the synthesis patent differ from patents covering Binimetinib's use?
Patents covering Binimetinib's use protect the application of the drug for specific medical conditions, such as treating melanoma. The synthesis patent, like WO2003077914A1, focuses on the chemical process of manufacturing the drug itself. This distinction is important for understanding market exclusivity and potential generic competition.
Who are the key players involved with Binimetinib patents?
The original applicant for WO2003077914A1 is Array BioPharma Inc. [1]. Array BioPharma was later acquired by Pfizer Inc. [3]. These companies are central to the development and patent protection of Binimetinib.
Can generic versions of Binimetinib be produced before patent expiry?
Generic production is typically only possible after the relevant patents, including those covering synthesis and use, have expired or been successfully challenged. The patent WO2003077914A1 pertains to the manufacturing process, and its expiry, along with other relevant patents, would be a prerequisite for generic entry [1].